Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward

Nature Reviews Clinical Oncology

Volumn 9, Issue 2, 2012, Pages 69-70

  Markman, Maurie ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN; OLAPARIB; PACLITAXEL;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; CLINICAL RESEARCH; EARLY DIAGNOSIS; GENE MUTATION; HIGH RISK POPULATION; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; TRANSVAGINAL ECHOGRAPHY;

CLINICAL TRIALS AS TOPIC; FEMALE; HISTORY, 21ST CENTURY; HUMANS; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 84856623785     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.200     Document Type: Review

References (7)

1. Buys, S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305, 2295-2303 (2011).
2. Nagle, C. M. et al. Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 29, 2253-2258 (2011).
3. Anderson, M. R. et al. Combining a symptoms index with CA125 to improve detection of ovarian cancer. Cancer 113, 484-489 (2008).
4. King, M. C. et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646 (2003).
5. Tan, D. S. et al. "BRCA-ness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 26, 5530-5536 (2008).
6. Yang, D. et al. Associations of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306, 1557-1565 (2011).
7. Pignata, S. et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J. Clin. Oncol. 29, 3628-3635 (2011).